Epidermal growth factor receptor antagonists companion diagnostics - QIAGEN

Drug Profile

Epidermal growth factor receptor antagonists companion diagnostics - QIAGEN

Alternative Names: Afatinib (Tovok) companion diagnostic - QIAGEN; Afatinib companion diagnostic - QIAGEN; Anti-EGFR companion diagnostic - QIAGEN; Cetuximab (Erbitux) companion diagnostic - QIAGEN; KRAS Gene Mutation Analysis, Colorectal cancer (cetuximab); Panitumumab (Vectibix) companion diagnostic - QIAGEN; therascreen EGFR RGQ PCR Kit (afatinib); Therascreen EGFR test - QIAGEN; therascreen KRAS RGQ PCR Kit (panitumumab); Therascreen KRAS test - QIAGEN

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QIAGEN
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 18 Jan 2018 US FDA approves label extension of therascreen® KRAS RGQ PCR Kit to include EGFR mutations L681Q, G719X and S768I for Non-small cell lung cancer (Diagnosis)
  • 23 May 2014 Registered for Non-small cell lung cancer (diagnosis) in China
  • 23 May 2014 US FDA approves therascreen® KRAS RGQ PCR Kit as a companion diagnostic for panitumumab for first-line, combination treatment of metastatic Colorectal cancer in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top